Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Aug 10:29:118-122.
doi: 10.1016/j.gore.2019.07.010. eCollection 2019 Aug.

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

Elizabeth K Lee  1 , Zhenying Tan-Wasielewski  2 , Ursula A Matulonis  1   3 , Michael J Birrer  4 , Alexi A Wright  1   3 , Neil Horowitz  3   5 , Panagiotis A Konstantinopoulos  1   3 , Jennifer Curtis  3 , Joyce F Liu  1   3
Affiliations
Case Reports

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

Elizabeth K Lee et al. Gynecol Oncol Rep. .

Erratum in

Abstract

Peripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy. HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemotherapy-induced peripheral neuropathy and furthermore has demonstrated synergistic antitumor activity with various chemotherapies. Here, we report the abbreviated results of a Phase Ib trial of ricolinostat, an HDAC6-specific inhibitor, in combination with paclitaxel, in the treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer.

Keywords: HDAC inhibitor; HDAC6; Ovarian cancer; Paclitaxel; Peripheral neuropathy; Taxane.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Swimmer's plot. Best overall responses (PD, SD, PR) are notated. ⁎One patient who withdrew from the study after receiving 1 cycle of treatment had stable disease at time of their follow-up assessment.
Fig. 2
Fig. 2
Waterfall plot. ⁎One patient who withdrew from the study after receiving 1 cycle of treatment had a percent difference of 0% in target lesions at time of their follow-up assessment.
See this image and copyright information in PMC

References

    1. Amengual J.E., Johannet P., Lombardo M., Zullo K., Hoehn D., Bhagat G., Scotto L., Jirau-serrano X., Radeski D., Heinen J., Jiang H., Cremers S., Zhang Y., Jones S., Connor O.A.O. Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor ACY-1215 and bortezomib is synergistic in lymphoma. Clin Cancer Res. 2015:4663–4676. - PMC - PubMed
    1. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., Rocha K., Kumaraswamy S., Boyapalle S., Atadja P., Seto E., Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 2005;280:26729–26734. - PubMed
    1. Bitler B.G., Wu S., Park P.H., Hai Y., Aird K.M., Wang Y., Zhai Y., Kossenkov A.V., Vara-Ailor A., Rauscher F.J., Zou W., Speicher D.W., Huntsman D.G., Conejo-Garcia J.R., Cho K.R., Christianson D.W., Zhang R. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat. Cell Biol. 2017;19:962–973. - PMC - PubMed
    1. Boyault C., Zhang Y., Fritah S., Caron C., Gilquin B., Kwon S.H., Garrido C., Yao T.-P., Vourc’h C., Matthias P., Khochbin S. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev. 2007;21:2172–2181. - PMC - PubMed
    1. Budman D.R., Tai J., Calabro A., John V. The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines. Investig. New Drugs. 2011;29:1224–1229. - PubMed

Publication types

LinkOut - more resources